- Global Pharma News & Resources

[2021] Infertility Drugs and Devices Market to Score Past US$ 9,702.4 Million Valuation by 2027 – Coherent Market Insights

SEATTLE, April 29, 2021, (PHARMIWEB) — Global Infertility Drugs and Devices Market


Infertility means not being able to become pregnant after a year of trying. Infertility drugs and devices are widely used to treat infertility in both males and females. Infertility treatment include in vitro fertilization, artificial insemination, surgery, Assisted Reproductive Technology (ART), and Drugs. Infertility is commonly caused by problems with ovulation. Hormonal disorders, tubal disorders, uterine disorders, ovarian disorders, and endometriosis are the major cause of female infertility, while erectile dysfunction, ejaculation disorders, varicocele, and azoospermia are the major cause of male infertility.

The global infertility drugs and devices market is expected to reach US$ 9,702.4 million by 2027.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@


High prevalence of infertility is expected to drive the global infertility drugs and devices market growth during the forecasted period. According to the National Survey of Family Growth (2018 report), in the U.S., around 15.5% of women who intend to become pregnant are infertile and 6.7% of married women aged between 15 to 44 years are infertile.

Furthermore, increase in homosexual population is expected to augment the growth of the global infertility drugs and devices market. According to Williams Institute at the UCLA School of Law, in 20219, around 4.5% of Americans were identified as gay, lesbian, transgender, or bisexual.


Expiry of drug patents and increasing awareness among people about infertility drugs and devices is expected to create significant growth opportunities for players active in the market. For instance, For instance, in September 2018, Eli Lilly and Company lost the patent protection of Cialis, a drug used to treat erectile dysfunction. While, Teva Pharmaceutical launched a generic version of Cialis in the United States in October 2018.


High cost of infertility treatment, the increasing prevalence of sexually transmitted diseases, and limited insurance coverage for assisted reproductive technology (ART) is expected to hamper the global infertility drugs and devices market growth. In Canada, the average cost of the infertility treatment ranges from US$ 10,000 to US$ 20,000. Moreover, there is limited fund for IVF (In vitro fertilization) and intracytoplasmic sperm injection.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @

Market Taxonomy:

By Drug Type:

  • Sex hormones
  • Metformin
  • Letrozole
  • Gonadotropins
  • Bromocriptine
  • Imipramine
  • Clomiphene citrate
  • Cabergoline

Infertility Devices:

  • Equipment
  • Accessories

By Gender:

  • Male
  • Female

By Region:

  • Asia Pacific
  • Europe
  • Africa
  • North America
  • Latin America
  • Middle East

View Press Release For More Information @

Competitive Section:

Key players active in the global infertility drugs and devices market are Dr. Reddy’s Laboratories, S.K. Chemicals Co. Ltd., Bayer AG, Cristalia Produtos Quimicos Farmaceuticos Ltd., Apricus Biosciences, Dong-A Pharmaceutical Co. Ltd., Ferring Pharmaceuticals, Meda Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer, Inc., Vivus, Inc. Mylan Pharmaceuticals Inc., Cipla Ltd, Aurobindo Pharma Ltd., Lupin Limited, Novartis International AG, Alembic Pharmaceuticals, Torrent Pharmaceuticals Ltd., Daré Bioscience, Inc., and Aspargo Laboratories, Inc.  

Key Developments:

In May 2020, Daré Bioscience and Health Decisions signed a partnership agreement to support the clinical development of Daré’s innovative pipeline of novel programs designed specifically to address persistent unmet needs in the areas of contraception, fertility, and broader gynecological disorders.

In September 2019, Lupin launched Sildenafil tablets, a generic version of Pfizer’s Viagra tablets. Sildenafil Tablets are a phosphodiesterase-5 (PDE5) inhibitor and are indicated for the treatment of erectile dysfunction (ED).

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 29-Apr-2021